But the stock has traded at less than a third of its 52-week high since Genentech, building on a string of clinical successes, released data showing that its Lucentis had unprecedented efficacy against some types of AMD, perhaps even reversing the disease.

FORBES: OSI Chief Explains $935 Million Eyetech Buy